INBX Stock Hit Record Highs: Cancer Therapies Reportedly Draw Big Pharma Interest

• The therapy, which is being tested alone and in combination with Keytruda, a prescription immunotherapy, could be valued at over $8 billion, according to the report.

• Inhibrx Biosciences could also spin off INBRX-106, along with another experimental cancer drug, into a separate entity.

• The biotech firm reported promising interim data from its Phase 1/2 trial for advanced colorectal cancer on Tuesday.

Shares of Inhibrx Biosciences (INBX) surged more than 40% on Wednesday to an all-time high, following reports of potential deal interest in its cancer pipeline, adding to momentum from encouraging early-stage colorectal cancer trial results.

All Eyes On INBRX-106

According to a Reuters report on Wednesday, Inhibrx Biosciences has attracted early-stage interest from major drugmakers including Merck & Co. (MRK), and Ono Pharmaceutical, for its experimental drug INBRX-106.

The therapy, which is being tested alone and in combination with Keytruda, a prescription immunotherapy, could be valued at over $8 billion if trials confirm its potential to boost treatment response rates.

The biotech firm could also spin off INBRX-106, along with another experimental cancer drug, into a separate entity that could be worth over $9 billion if trials are successful.

New Cancer Drug Shows Promise

Meanwhile, its second key asset, Ozekibart, is also gaining traction after Inhibrx Biosciences reported interim Phase 1/2 data for advanced colorectal cancer, showing promising results in pretreated patients.

Among 45 patients, the treatment achieved a 20% response rate, well above the typical 1% - 6% seen with standard therapies. Nearly half of these responses lasted more than six months. The median progression-free survival was 5.5 months, and 42% of patients remained progression-free at 6 months.

The therapy also showed a manageable safety profile, with mostly mild to moderate side effects such as diarrhea, fatigue, and nausea. Inhibrx plans to meet with the U.S. Food and Drug Administration (FDA) later this year to discuss advancing the treatment into late-stage trials.

INBX Stock: How Did Retail Traders React?

Retail sentiment on Stocktwits for INBX turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘high’ message volumes.

One user noted “very strong data” from the Ozekibart trial.

Another user was bullish about the firm’s prospects.

Year-to-date, the stock has gained around 5%.

For updates and corrections, email newsroom[at]stocktwits[dot]com.